Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110720 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
A Phase 2 study of Progressive Supranuclear Palsy, sponsored by Allon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 313
- Enrollment target
- 20
- Study locations
NCT01110720 is a Phase 2 study of Progressive Supranuclear Palsy that has completed, run by Allon Therapeutics. The registered enrollment target is 313 participants, below the 435-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT01110720, a Phase 2 study of Progressive Supranuclear Palsy, has completed, sponsored by Allon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 313 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Davunetide
Study Locations (20)
California
- USC Keck School of Medicine - Los Angeles
- David Geffen School of Medicine - UCLA - Los Angeles
- UCSD/VA Neurology Service - San Diego
- UCSF Memory and Aging Center - San Francisco
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Mayo Clinic, Florida - Jacksonville
- The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF - Tampa
Arizona
- Muhammed Ali Parkinson Center and Movement Disorders Clinic - Phoenix
- Mayo Clinic, AZ - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
- Lahey Clinic - Burlington
Minnesota
- University of Minnesota Department of Neuology - Minneapolis
- Mayo Clinic, Rochester, MN - Rochester
Alabama
- University of Alabama - Birmingham - Birmingham
Colorado
- Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC - Englewood
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110720
The ClinicalTrials.gov registry entry for NCT01110720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 435-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (28% lower). The listed sponsor is Allon Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01110720 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01110720 about?
NCT01110720 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy". The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
What is the current status of trial NCT01110720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 313 participants. The study started on 2010-10. Estimated completion is 2012-12.
What conditions does trial NCT01110720 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT01110720?
The interventions under investigation include: Placebo (DRUG), Davunetide (DRUG).
Who is sponsoring clinical trial NCT01110720?
This trial is sponsored by Allon Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110720 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
ACTIVE NOT RECRUITING · Phase 2
-
AMX0035 and Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Coenzyme Q10 in PSP and CBD
COMPLETED · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Gait Analysis in Neurological Disease
RECRUITING
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.